{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:05:41Z","timestamp":1769241941101,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UAMS Department of Pharmacology and Toxicology"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIDA","award":["DA039143"],"award-info":[{"award-number":["DA039143"]}]},{"name":"NIH","award":["AR062012"],"award-info":[{"award-number":["AR062012"]}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","award":["AR068509"],"award-info":[{"award-number":["AR068509"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.taap.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T15:33:32Z","timestamp":1528817612000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects"],"prefix":"10.1016","volume":"353","author":[{"given":"Lirit N.","family":"Franks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Prather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2018.06.009_bb0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.canlet.2009.04.005","article-title":"Cannabinoids in the treatment of cancer","volume":"285","author":"Alexander","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2018.06.009_bb0010","first-page":"147","article-title":"Emerging therapies for the treatment of osteoporosis","volume":"4","author":"Bhutani","year":"2013","journal-title":"J. Midlife Health"},{"key":"10.1016\/j.taap.2018.06.009_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0020","doi-asserted-by":"crossref","first-page":"22330","DOI":"10.1074\/jbc.272.35.22330","article-title":"A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor\/ligand interactions","volume":"272","author":"Bouaboula","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2018.06.009_bb0025","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1021\/bi500632a","article-title":"Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors","volume":"53","author":"Brailoiu","year":"2014","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.taap.2018.06.009_bb0030","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.taap.2018.06.009_bb0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11481-015-9615-z","article-title":"Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function","volume":"10","author":"Cabral","year":"2015","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0040","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (i50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. A","key":"10.1016\/j.taap.2018.06.009_bb0045","doi-asserted-by":"crossref","first-page":"44A","DOI":"10.1155\/2005\/894781","article-title":"Guidelines for the use of cannabinoid compounds in chronic pain","volume":"10","author":"Clark","year":"2005","journal-title":"Pain Res. Manag."},{"key":"10.1016\/j.taap.2018.06.009_bb0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1567-5769(01)00086-8","article-title":"Nitric oxide in immunity and inflammation","volume":"1","author":"Coleman","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/1098-2396(20001215)38:4<477::AID-SYN13>3.0.CO;2-Y","article-title":"Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist\/inverse agonist AM281","volume":"38","author":"Cosenza","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.taap.2018.06.009_bb0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.116.232561","article-title":"Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway","volume":"358","author":"Dhopeshwarkar","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2018.06.009_bb0065","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/mc.22251","article-title":"Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption","volume":"54","author":"Feng","year":"2015","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.taap.2018.06.009_bb0070","article-title":"Tamoxifen isomers and metabolites exhibit distinct affinity and activity at cannabinoid receptors: potential scaffold for drug development","volume":"9","author":"Ford","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2018.06.009_bb0075","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease","volume":"163","author":"Garcia","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.taap.2018.06.009_bb0080","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2174\/138955712800959143","article-title":"Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations","volume":"12","author":"Goupil","year":"2012","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.taap.2018.06.009_bb0085","first-page":"495","article-title":"The therapeutic potential of cannabis and cannabinoids","volume":"109","author":"Grotenhermen","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.taap.2018.06.009_bb0090","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2013.08.020","article-title":"Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway","volume":"86","author":"Guo","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/bpb.b13-00129","article-title":"Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines","volume":"36","author":"Guo","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.taap.2018.06.009_bb0100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/bjc.2015.464","article-title":"Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer","volume":"114","author":"Hilborn","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2018.06.009_bb0105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3892\/br.2015.469","article-title":"A synergistic interaction of 17-beta-estradiol with specific cannabinoid receptor type 2 antagonist\/inverse agonist on proliferation activity in primary human osteoblasts","volume":"3","author":"Hojnik","year":"2015","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.taap.2018.06.009_bb0110","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2215\/CJN.07590714","article-title":"Cytokines: names and numbers you should care about","volume":"10","author":"Holdsworth","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.taap.2018.06.009_bb0115","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm1255","article-title":"Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors","volume":"11","author":"Idris","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2018.06.009_bb0120","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1210\/en.2008-0150","article-title":"Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor","volume":"149","author":"Idris","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.taap.2018.06.009_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.108.000992","article-title":"Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery","volume":"62","author":"Kenakin","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2018.06.009_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbrc.2013.04.040","article-title":"Identification of raloxifene as a novel CB2 inverse agonist","volume":"435","author":"Kumar","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2018.06.009_bb0135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.leukres.2005.01.014","article-title":"Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells","volume":"29","author":"Lombard","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.taap.2018.06.009_bb0140","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.bjp.0707480","article-title":"Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists","volume":"153","author":"Lunn","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2006.05.040","article-title":"The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis","volume":"542","author":"Maekawa","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0150","first-page":"1","article-title":"Tamoxifen action in ER-negative breast cancer","volume":"5","author":"Manna","year":"2016","journal-title":"Sign. Transduct. Insights"},{"key":"10.1016\/j.taap.2018.06.009_bb0155","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-15-0857","article-title":"ERRalpha is a marker of tamoxifen response and survival in triple-negative breast cancer","volume":"22","author":"Manna","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2018.06.009_bb0160","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.taap.2018.06.009_bb0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood-2002-01-0098","article-title":"Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease","volume":"100","author":"Mckallip","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.06.009_bb0175","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/mol.106.023937","article-title":"Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression","volume":"70","author":"Mckallip","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0180","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.phrs.2012.08.002","article-title":"The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons","volume":"66","author":"Murataeva","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.taap.2018.06.009_bb0185","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1349-7006.2007.00709.x","article-title":"Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B","volume":"99","author":"Nagahara","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.taap.2018.06.009_bb0190","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbrc.2013.05.040","article-title":"Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement","volume":"435","author":"Nagahara","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2018.06.009_bb0195","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/ml3004236","article-title":"Trisubstituted sulfonamides: a new chemotype for development of potent and selective CB2 receptor inverse agonists","volume":"4","author":"Ouyang","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.taap.2018.06.009_bb0200","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.7314\/APJCP.2015.16.12.4863","article-title":"Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer","volume":"16","author":"Payandeh","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2018.06.009_bb0205","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.taap.2018.06.009_bb0210","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.taap.2018.06.009_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2016.08.004","article-title":"Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease","volume":"48","author":"Poirier","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.taap.2018.06.009_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2013.10.057","article-title":"CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen","volume":"441","author":"Prather","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2018.06.009_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.159","article-title":"Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist","volume":"3","author":"Presley","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.taap.2018.06.009_bb0230","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.bmc.2015.07.057","article-title":"Synthesis and biological evaluation of (3\u2032,5\u2032-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl\/alkyl-methanone selective CB2 inverse agonist","volume":"23","author":"Presley","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2018.06.009_bb0235","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","article-title":"Inflammasome complexes: emerging mechanisms and effector functions","volume":"165","author":"Rathinam","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.taap.2018.06.009_bb0240","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/ijms16010758","article-title":"Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189","volume":"16","author":"Reiner","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2018.06.009_bb0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4142\/jvs.2002.3.3.179","article-title":"SR144528 as inverse agonist of CB2 cannabinoid receptor","volume":"3","author":"Rhee","year":"2002","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.taap.2018.06.009_bb0250","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjp.0702351","article-title":"Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630","volume":"126","author":"Ross","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0255","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.chembiol.2011.05.012","article-title":"Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists","volume":"18","author":"Schuehly","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.taap.2018.06.009_bb0260","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bcp.2007.11.005","article-title":"Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents","volume":"75","author":"Shiina","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0265","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1124\/jpet.105.085282","article-title":"The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors","volume":"314","author":"Shoemaker","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2018.06.009_bb0270","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/jpet.105.089474","article-title":"Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors","volume":"315","author":"Shoemaker","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2018.06.009_bb0275","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/tox.22154","article-title":"Effects of xenoestrogens in human M1 and M2 macrophage migration, cytokine release, and estrogen-related signaling pathways","volume":"31","author":"Teixeira","year":"2016","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.taap.2018.06.009_bb0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bmc.2012.10.037","article-title":"Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2","volume":"21","author":"Tsukuda","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2018.06.009_bb0285","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.taap.2018.06.009_bb0290","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2005.08.013","article-title":"Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice","volume":"520","author":"Ueda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0295","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lfs.2006.09.026","article-title":"Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice","volume":"80","author":"Ueda","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.taap.2018.06.009_bb0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.taap.2018.06.009_bb0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14712\/fb2012058020075","article-title":"Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation","volume":"58","author":"Vidinsky","year":"2012","journal-title":"Folia Biol. (Praha)"},{"key":"10.1016\/j.taap.2018.06.009_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.106","article-title":"WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells","volume":"2","author":"Wasik","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2018.06.009_bb0315","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.pain.2012.02.015","article-title":"Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels","volume":"153","author":"Wilkerson","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.taap.2018.06.009_bb0320","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1021\/jm3017464","article-title":"Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.taap.2018.06.009_bb0325","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/sj.bjp.0707568","article-title":"In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB(2) receptor?","volume":"153","author":"Yao","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.06.009_bb0330","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12031-016-0785-9","article-title":"Raloxifene and tamoxifen reduce PARP activity, cytokine and oxidative stress levels in the brain and blood of ovariectomized rats","volume":"60","author":"Yazgan","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.taap.2018.06.009_bb0335","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00223-015-9967-7","article-title":"Ubiquitin E3 ligase LNX2 is critical for osteoclastogenesis in vitro by regulating M-CSF\/RANKL signaling and Notch2","volume":"96","author":"Zhou","year":"2015","journal-title":"Calcif. Tissue Int."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18302679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18302679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:57:55Z","timestamp":1751684275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X18302679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":67,"alternative-id":["S0041008X18302679"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2018.06.009","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}